TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17961145

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Oral 17‐beta estradiol
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Oral and vaginal 17‐beta estradiol
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 169
Study: 16632842

Group type: COMPARATOR
Intervention: Continuous spinal anesthesia (CSA) with titration of 2.5 mg boluses every 15 min of isobaric bupivacaine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Single injection spinal anesthesia (SA) with 7.5 mg of isobaric bupivacaine
Number of subjects: 74
Study: 11267624

Group type: EXPERIMENTAL
Intervention: 5 mg oral hydrocortisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg oral hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9884705

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (40 Gy)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined treatment (surgery + radiotherapy)
Number of subjects: 81
Study: 7857512

Group type: EXPERIMENTAL
Intervention: Hypericum extracts (dosage: 300 to 900 mg total extract daily; duration: 2 to 6 weeks)
Number of subjects: 1592

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1592
Study: 2543207

Group type: EXPERIMENTAL
Intervention: CAVE chemotherapy + RA233
Number of subjects: 101

Group type: COMPARATOR
Intervention: CAVE chemotherapy
Number of subjects: 101
Study: 132780

Group type: EXPERIMENTAL
Intervention: Desoximetasone (0.25%)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fluocinolone acetonide (0.2%)
Number of subjects: 37
Study: 29877128

Group type: EXPERIMENTAL
Intervention: n-back training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Active control group (general knowledge and vocabulary task)
Number of subjects: 41
Study: 29426608

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) at a dose of 10 mg/kg intravenously, 10 min preoperatively and 5 h postoperatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 100
Study: 26224543

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg once daily, n=125)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo (n=128)
Number of subjects: 253
Study: 23519040

Group type: EXPERIMENTAL
Intervention: Western healthcare class (36% of participants)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Eastern healthcare class (18% of participants)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Mixed healthcare class (46% of participants)
Number of subjects: 327
Study: 22658688

Group type: EXPERIMENTAL
Intervention: Physio group (closed venous reservoir, phosphorylcholine coating, and no cardiotomy suction)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard group (open, noncoated, and cardiotomy suction used)
Number of subjects: 83
Study: 19907419

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18549992

Group type: EXPERIMENTAL
Intervention: Energy deficit of at least 500 kcal per day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Self-monitoring adherence
Number of subjects: 54
Study: 15987049

Group type: EXPERIMENTAL
Intervention: Pacemaker use for therapeutic prevention of atrial fibrillation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overdrive pacing and different preventive pacing algorithms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dual site pacing or septal pacing
Number of subjects: 16
Study: 12732880

Group type: EXPERIMENTAL
Intervention: G‐CSF alone (10 mcg/kg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cyclophosphamide plus G‐CSF (Cyclophosphamide at 4 g/m(2) and G‐CSF at 10 mcg/kg/day)
Number of subjects: 52
Study: 10199772

Group type: EXPERIMENTAL
Intervention: GHRP-2 plus TRH infusion (1 + 1 microg/kg x h) for 5 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion for 5 days
Number of subjects: 14
Study: 7767416

Group type: EXPERIMENTAL
Intervention: Plain abdominal roentgenogram
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rectal examination
Number of subjects: 60
Study: 2095530

Group type: EXPERIMENTAL
Intervention: Load 1 - 75% sound leg mass
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Load 2 - 100% sound leg mass
Number of subjects: 6

Group type: COMPARATOR
Intervention: Load 0 - unloaded (39.1% sound shank mass)
Number of subjects: 6
Study: 348293

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide, adriamycin, and 5‐fluorouracil (CAF)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Combination of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 78

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CAF and CMF
Number of subjects: 78
Study: 31286426

Group type: EXPERIMENTAL
Intervention: Hand hygiene education programme with digital tools (interactive android-based tablets)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 377
Study: 30040076

Group type: EXPERIMENTAL
Intervention: Efgartigimod (FcRn antagonist)
Number of subjects: 62
Study: 25982568

Group type: EXPERIMENTAL
Intervention: Combined setting of one night wake therapy followed by 2 weeks bright light therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bright light therapy alone
Number of subjects: 62
Study: 24176585

Group type: EXPERIMENTAL
Intervention: Airway scope (AWS)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MLS)
Number of subjects: 109
Study: 22231691

Group type: EXPERIMENTAL
Intervention: Shaoyang‐specific acupuncture
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Shaoyang‐nonspecific acupuncture
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Yangming‐specific acupuncture
Number of subjects: 480

Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 480
Study: 21220791

Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16919506

Group type: EXPERIMENTAL
Intervention: Drug therapy with sustained-release tolterodine alone
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Drug therapy with sustained-release tolterodine combined with behavioral training (pelvic floor muscle exercise training, bladder control techniques, fluid management)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (drug withdrawal and behavioral training stopped)
Number of subjects: 307
Study: 16563280

Group type: EXPERIMENTAL
Intervention: Weight-adjusted dose rt-PA (42-92 mg, 1 mg/kg body weight)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Low dose rt-PA (42 mg over 90 minutes)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Weight-adjusted dose rt-PA
Number of subjects: 184

Group type: COMPARATOR
Intervention: Low dose rt-PA
Number of subjects: 184
Study: 12189776

Group type: EXPERIMENTAL
Intervention: Chewing gums (Superpep forte, 20 mg dimenhydrinate each, chewed for 30 min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 mg dimenhydrinate tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chewing gums (Superpep forte)
Number of subjects: 24
Study: 10596517

Group type: EXPERIMENTAL
Intervention: 6‐hr video‐based small group motivational‐skills intervention
Number of subjects: 117

Group type: COMPARATOR
Intervention: 6‐hr video‐based contact‐matched HIV education comparison group
Number of subjects: 117
Study: 7851574

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) depot, 1.88 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) depot, 3.75 mg
Number of subjects: 36
Study: 1723456

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 6935550

Group type: EXPERIMENTAL
Intervention: gemfibrozil (1600 mg daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study: 31480373

Group type: EXPERIMENTAL
Intervention: Human milk samples from mothers without celiac disease
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Human milk samples from mothers with celiac disease
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Human milk samples from different countries
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Human milk samples analyzed for IGF‐II and adiponectin
Number of subjects: 569
Study: 28622941

Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose (LD)
Number of subjects: 1862
Study: 27381202

Group type: EXPERIMENTAL
Intervention: Family-based pulmonary rehabilitation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional pulmonary rehabilitation
Number of subjects: 20
Study: 25407420

Group type: EXPERIMENTAL
Intervention: Handwashing with soap
Number of subjects: 0

Group type: COMPARATOR
Intervention: No handwashing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child care activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agricultural activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food preparation activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water access, latrine type, education, or diarrhoea
Number of subjects: 0
Study: 22431131

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day orally
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19837431

Group type: EXPERIMENTAL
Intervention: 140 mA seconds
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 100 mA seconds
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 60 mA seconds
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30 mA seconds
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 15 mA seconds
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 7.5 mA seconds
Number of subjects: 14
Study: 17211699

Group type: EXPERIMENTAL
Intervention: Synbiotic 2000 (once daily dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15851339

Group type: EXPERIMENTAL
Intervention: Stimulation at anterior coronary vein
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stimulation at lateral coronary vein
Number of subjects: 24

Group type: COMPARATOR
Intervention: Overall stimulation at different sites within a coronary vein
Number of subjects: 24
Study: 11999569

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined therapy (radiotherapy followed by chemotherapy)
Number of subjects: 48
Study: 9802715

Group type: EXPERIMENTAL
Intervention: Metronidazole 25% dental gel applied subgingivally on days 0 and 7
Number of subjects: 46

Group type: COMPARATOR
Intervention: Scaling and root planing carried out on days 0 and 7
Number of subjects: 46
Study: 8178002

Group type: EXPERIMENTAL
Intervention: 100% O2 exposure (prior O2 exposure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambient air (without prior O2 exposure)
Number of subjects: 0
Study: 3722633

Group type: COMPARATOR
Intervention: Nasal challenge with saline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nasal challenge with Bermuda grass-pollen allergen
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nasal challenge with histamine
Number of subjects: 11
Study: 29774884

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided radial arterial cannulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional blind puncture method
Number of subjects: 120
Study: 27752485

Group type: EXPERIMENTAL
Intervention: Mindfulness-integrated cognitive behavior therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine prenatal care services
Number of subjects: 80
Study: 24993098

Group type: EXPERIMENTAL
Intervention: Short-term continuous positive airway pressure (CPAP), n=22, duration 6-8 weeks.
Number of subjects: 45

Group type: COMPARATOR
Intervention: No CPAP, n=23.
Number of subjects: 45
Study: 22727611

Group type: COMPARATOR
Intervention: Warfarin 25 mg alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Warfarin 25 mg coadministered with fimasartan 240 mg
Number of subjects: 15
Study: 20942292

Group type: EXPERIMENTAL
Intervention: Tuina massage therapy
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Acupoint injection
Number of subjects: 937

Group type: COMPARATOR
Intervention: Tuina
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Tuina massage
Number of subjects: 937
Study: 17069892

Group type: EXPERIMENTAL
Intervention: Wearable finger flexion monitor
Number of subjects: 30
Study: 16337870

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease subjects
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy elderly subjects
Number of subjects: 3

Group type: COMPARATOR
Intervention: Young adult subjects
Number of subjects: 3
Study: 11788225

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 24322

Group type: COMPARATOR
Intervention: Conventional therapy (diuretics or beta-blockers)
Number of subjects: 24322

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 24322
Study: 10209370

Group type: EXPERIMENTAL
Intervention: Orange-flavoured glucose (group I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-fat milk (group II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Breast milk (group III)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Midnight fast (group IV)
Number of subjects: 45
Study: 7726351

Group type: EXPERIMENTAL
Intervention: Intraarticular injection of 20 ml of 1% lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous injections of morphine sulfate and midazolam
Number of subjects: 30
Study: 2292351

Group type: EXPERIMENTAL
Intervention: Aluminum phosphate
Number of subjects: 91

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 91
Study: 7211734

Group type: EXPERIMENTAL
Intervention: Skim milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yoghurt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full cream milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (skim milk, yoghurt, full cream milk)
Number of subjects: 0
Study: 31983312

Group type: EXPERIMENTAL
Intervention: Intensive BP goal (<120 mm Hg)
Number of subjects: 2270

Group type: COMPARATOR
Intervention: Standard BP goal (<140 mm Hg)
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: Both BP goals
Number of subjects: 2270
Study: 30685701

Group type: EXPERIMENTAL
Intervention: Low-dose buprenorphine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 28524806

Group type: EXPERIMENTAL
Intervention: Vigorous exercise intervention
Number of subjects: 214

Group type: COMPARATOR
Intervention: Health education intervention
Number of subjects: 214
Study: 25828601

Group type: EXPERIMENTAL
Intervention: His-bundle pacing (HBP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Biventricular pacing (BiVP)
Number of subjects: 29
Study: 24067797

Group type: EXPERIMENTAL
Intervention: EPA/DHA-rich liquid diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Liquid diet lacking EPA/DHA
Number of subjects: 30
Study: 21422081

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 19280831

Group type: EXPERIMENTAL
Intervention: GTR + CAF
Number of subjects: 7

Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 7
Study: 17267744

Group type: EXPERIMENTAL
Intervention: FIR therapy for 1 year
Number of subjects: 145
Study: 16221350

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: N-NNS (control)
Number of subjects: 38
Study: 11254512

Group type: EXPERIMENTAL
Intervention: Premenopausal women
Number of subjects: 12219

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with hormone replacement therapy (HRT)
Number of subjects: 12219

Group type: EXPERIMENTAL
Intervention: Postmenopausal women without HRT
Number of subjects: 12219

Group type: COMPARATOR
Intervention: Men
Number of subjects: 12219

Group type: COMPARATOR
Intervention: Overall comparison of sleep apnea prevalence
Number of subjects: 12219

Group type: COMPARATOR
Intervention: Postmenopausal women without HRT compared to premenopausal women with HRT
Number of subjects: 12219

Group type: COMPARATOR
Intervention: Postmenopausal women without HRT compared to men
Number of subjects: 12219
Study: 9635849

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 20
Study: 7596206

Group type: EXPERIMENTAL
Intervention: Integrated Inpatient Management Model (clinical information system)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control service (historic norms)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control service
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Other internal medicine services
Number of subjects: 2000
Study: 2551204

Group type: COMPARATOR
Intervention: BID regimen (twice a day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: QID regimen (four times a day)
Number of subjects: 53
Study: 776326

Group type: EXPERIMENTAL
Intervention: Ultra-clean air theatre
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional theatre
Number of subjects: 0
Study: 30418579

Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA (2.4 g daily)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 699
Study: 28614905

Group type: EXPERIMENTAL
Intervention: ROAD (rituximab, oxaliplatin, cytarabine, dexamethasone)
Number of subjects: 45
Study: 26100924

Group type: EXPERIMENTAL
Intervention: 90μg HPV vaccine
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: 60μg HPV vaccine
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: 30μg HPV vaccine
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Control hepatitis B vaccine
Number of subjects: 1600
Study: 22906966

Group type: EXPERIMENTAL
Intervention: Autopulse™ ZOLL mechanical CPR device with 'pit-crew' protocol
Number of subjects: 248
Study: 20337634

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.i.d. on Day 5 of a 7-day regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laropiprant 40 mg alone
Number of subjects: 0
Study: 19298202

Group type: EXPERIMENTAL
Intervention: HP-diet
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: L-diet
Number of subjects: 35

Group type: COMPARATOR
Intervention: C-diet
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: FF-diet
Number of subjects: 35
Study: 17643983

Group type: EXPERIMENTAL
Intervention: No anxiety whilst awaiting the PSA test results
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: High levels of anxiety whilst awaiting the PSA test results
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Anxiety influenced by previously elevated PSA tests
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: No anxiety associated with biopsy
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: High levels of anxiety associated with biopsy
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Levels of anxiety with subsequent rounds of examinations
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Levels of anxiety with increasing age
Number of subjects: 1781
Study: 15571110

Group type: EXPERIMENTAL
Intervention: Full intervention (FI) school
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Semi-intervention (SI) school
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (C) school
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Before summer vacation measurements
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: After summer vacation measurements
Number of subjects: 3
Study: 11276502

Group type: EXPERIMENTAL
Intervention: Newborns of smoking mothers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Newborns of non-smoking mothers
Number of subjects: 0
Study: 11229106

Group type: EXPERIMENTAL
Intervention: prazosin GITS 2.5 mg OD
Number of subjects: 24

Group type: COMPARATOR
Intervention: atenolol 50 mg OD
Number of subjects: 24

Group type: COMPARATOR
Intervention: nifedipine SR 20 mg BD
Number of subjects: 24

Group type: COMPARATOR
Intervention: enalapril 5 mg OD
Number of subjects: 24
Study: 7887113

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rocuronium (2 x ED90) and Vecuronium (1/2 x ED90)
Number of subjects: 32

Group type: COMPARATOR
Intervention: EMG TOF ratio
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: First dorsal interosseous EMG amplitude and area
Number of subjects: 32
Study: 3497450

Group type: EXPERIMENTAL
Intervention: Norfloxacin (1200 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cotrimoxazole (480/2400 mg)
Number of subjects: 53
Study: 29104121

Group type: EXPERIMENTAL
Intervention: Vesatolimod (1-, 2-, or 4-mg doses) administered once weekly for 4, 8, or 12 weeks
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo (PBO) administered once weekly for 4, 8, or 12 weeks
Number of subjects: 162
Study: 28342578

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441mg
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882mg
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 26378397

Group type: EXPERIMENTAL
Intervention: Expedited care pathway (24-h admission)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (72-h admission)
Number of subjects: 40
Study: 23383976

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program (8 weeks)
Number of subjects: 100
Study: 21667452

Group type: EXPERIMENTAL
Intervention: 10-hour social skills training (TEAM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated waiting control group
Number of subjects: 40
Study: 19807952

Group type: EXPERIMENTAL
Intervention: Access to comprehensive electronic medical records (EMRs)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No access to comprehensive EMRs
Number of subjects: 61
Study: 16998266

Group type: EXPERIMENTAL
Intervention: Candesartan (angiotensin II type 1 receptor blocker)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Amlodipine (dihydropiridine calcium antagonist)
Number of subjects: 400